PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)67125-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)67125-2/fulltext
Title :
PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67125-2&doi=10.1016/S1098-3015(10)67125-2
First page :
Section Title :
Open access? :
No
Section Order :
960